August 27, 2019
SAN DIEGO, CA. – Riptide Bioscience President Dr. George Martin today delivered a poster presentation at the 2019 IPF Summit, the largest industry event specifically focused on translational programs in Idiopathic Pulmonary Fibrosis.
August 19, 2019
SAN FRANCISCO, CA. – Riptide Bioscience, Inc announces that the results of its research on the development of a novel antimicrobial peptide for the treatment of infected wounds have been published in the journal Frontiers in Microbiology.
July 28, 2019
CAMBRIDGE, UK – Dr. Henry Lopez, Executive Vice President of Riptide Bioscience, today addressed the International Workshop on Scleroderma Research (IWSR). The Workshop, co-sponsored by the University of Pittsburgh and University College London, is the largest international meeting devoted to pathogenic mechanisms in systemic scleroderma (SSc).
Riptide Bioscience Announces NCI Contract to Evaluate RP Drug Candidates in Combination with Radiotherapy
October 8, 2018
SAN FRANCISCO, CA. – Riptide Bioscience, Inc., today announced that it has been awarded a $299,000 contract from the National Cancer Institute to evaluate its proprietary drug candidate, RP-185, in combination with radiotherapy.
September 19, 2018
SAN FRANCISCO, CA. – Riptide Bioscience, Inc., announced that it has been awarded a $227,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to develop peptide therapeutics targeting diabetic foot ulcers.